wobbleg

This poster presents a novel liquid biopsy platform that leverages advanced long-read RNA sequencing to uncover cancer-specific transcript isoforms in breast cancer patients. By combining comprehensive transcriptome profiling with proprietary analytical approaches, the technology enables highly accurate detection of tumor-derived signals from blood samples, revealing thousands of previously uncharacterized RNA variants. The platform not only improves diagnostic precision but also identifies new therapeutic targets, supporting applications across early detection, treatment monitoring, and drug development.

Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, will today present new data at the San Antonio Breast Cancer Symposium (SABCS) that demonstrates the ability of its technology platform to provide deep biological insights critical for drug discovery and development, building on previous data which established the technology’s strong predictive performance as a diagnostic tool.

UK startup Wobble Genomics is eyeing the breast cancer early detection market with technology that enables it to capture rare and low-abundance RNA transcripts.

Mercia Ventures-backed Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing.

Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, will present data today demonstrating that its technology can detect rare full-length RNA transcript variants not picked up by other methods.

This poster showcases Wobble Genomics’ novel liquid biopsy platform, which combines long-read RNA sequencing with proprietary Level-Up normalization to uncover previously undetectable RNA signals in blood. Using whole transcriptome profiling from breast cancer patients and controls, the study demonstrates how full-length RNA can significantly improve early cancer detection. By revealing hundreds of thousands of novel transcripts and enhancing predictive accuracy, this approach opens new avenues for sensitive diagnostics and deeper insights into cancer biology.

The University of Edinburgh spinout’s novel approach to RNA sequencing could revolutionise biotech.

An Edinburgh University spin-out which is working on methods to revolutionise the early detection of cancer has raised £8.5 million to help commercialise its technology.

Wobble Genomics presents a novel approach to RNA sequencing with its Level-Up full-length cDNA normalization technology, designed to reveal the full complexity of the transcriptome. By reducing the dominance of highly abundant transcripts and enhancing the detection of low-abundance isoforms, Level-Up significantly improves gene discovery and transcript coverage without requiring prior target selection. Compatible with long-read sequencing platforms, this method increases sensitivity, lowers sequencing costs, and enables a more complete and unbiased view of RNA biology—unlocking deeper insights for research and clinical applications.

Developments in high-performance computing and high-throughput hardware are advancing emerging computational biology trends.